doi:10.3969/j.issn.1673-8640.2021.05.024

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 11

[1]	FANG L F, ZHANG P P, WANG J, et al. Clinical and microbiological characteristics of cryptococcosis at an university hospital in China from 2013 to 2017[J]. Braz J Infect Dis, 2020,24(1):7-12. DOI URL
[2]	ALMEIDA A, FENAUX P, LIST A F, et al. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes(MDS)[J]. Leuk Res, 2017,52:50-57. DOI URL
[3]	GIAGOUNIDIS A A, KULASEKARARAJ A, GERMING U, et al. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide[J]. Leukemia, 2012,26(4):855-858. DOI URL
[4]	韩冰, 李红敏, 陈芳菲, 等. 骨髓增生异常综合征贫血原因及治疗策略[J]. 天津医药, 2018,46(8):794-798.
[5]	中华医学会血液学分会. 骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志, 2019,40(2):89-97.
[6]	宋慧娟, 张卫军, 牟锐, 等. MDS(5q-)伴环铁增多及SF3B1基因突变一例及治疗观察[J]. 临床医药文献电子杂志, 2019,6(86):179.
[7]	贡蓉, 贺少龙, 王涛, 等. 环磷酰胺联合环孢素治疗输血依赖的MDS 5q合并自身免疫性溶血性贫血一例[J]. 山西医药杂志, 2017,46(23):2962-2963.
[8]	年青, 王利. 伴del(5q)的骨髓增生异常综合征的分子生物学研究进展[J]. 重庆医科大学学报, 2015,40(4):542-545.
[9]	GORSHEIN E, WEBER U M, GORE S. Higher-risk myelodysplastic syndromes with del(5q):does the del(5q) matter?[J]. Expert Rev Hematol, 2020,13(3):233-239. DOI URL
[10]	冯秀媛, 闫慧明, 王永福, 等. 系统性红斑狼疮血液系统受累的相关性分析[J]. 临床荟萃, 2011,26(23):2086-2088.
[11]	杨朝荣. 误诊为血液系统疾病的系统性红斑狼疮临床分析[J]. 中国热带医学, 2010,10(9):1135.

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 11

Related Articles 15

Recommended Articles

Metrics